Vivus CEO Leland Wilson saw “a very powerful signal” that anti-obesity drug Qnexa would be approved.
Should you ditch JNJ stock if you had to raise capital? Warren Buffett said he would. Discussing whether investors should keep JNJ in their portfolios, with Les Funtleyder, Miller Tabak healthcare strategist.
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
There will be no silver bullet to reduce obesity, says Margaret Hamburg, FDA commissioner. Adding that, "generic drugs make a huge difference in patient care."
What investors should take away from Vivus, as shares soar on FDA nod.
A serious warning is out to patients, doctors and hospitals telling everyone to beware of a fake version of Roche's cancer-fighting drug Avastin. Insight with Scott Gottlieb, MD.
Perrigo CEO Joseph Papa appeared on Wednesday's "Mad Money."
Perrigo CEO, Joseph Papa discusses his company's 11% Q2 profit rise, and its outlook on growth, with Mad Money's Jim Cramer.
A breakdown of the drug-maker's Q4 profit after reporting a loss a year earlier, with Andrew Witty, GlaxoSmithKline CEO.
Insight on the value that will be created by a transaction with Illumina, with Severin Schwan, Roche CEO, who discusses Roche's offer for Illumina.
During his presidential campaign in 2007, Republican candidate Mitt Romney promised that a trust overseeing his financial portfolio would shed any investments that conflicted with GOP positions toward Iran, China, stem cell research and other issues.
A breakdown of the pharmaceutical giant's earnings, with John Eade, Argus Research.
Weighing in on the pharmaceuticals company's fourth quarter earnings, with John Lechleiter, Eli Lilly chairman/president/CEO, who discusses patent expiration and the impact on business.
It’s rare for the world's leading pharmaceutical companies and other partners to work together to tackle an urgent global health issue. It’s time for this to change and our new coordinated effort – unlike previous siloed, disease-by-disease approaches – is the first step.
Cramer thinks big pharma stocks could soon pop, so here's his preferred plays.
Find out why he’s bullish on this biotech name.
Mad Money's Cramer, explains why Sanofi-Aventis is his favorite medical breakthrough stock, saying it has excellent management; its growth platforms are working; and it supplies a juicy dividend.
Paula Deen has been teaching comfort food cooks since 2002. On January 17, 2012, she announced her diagnosis of Type 2 diabetes. She also announced that she had become the spokesperson for the anti-diabetes drug Victoza. However, she’s hardly the only celebrity chef to make a questionable endorsement deal.
Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.
And here’s how the “Mad Money” host suggests playing it.